Cue Biopharma, Inc. (CUE) Social Stream

Cue Biopharma, Inc. (CUE): $1.35

0.05 (+3.85%)

POWR Rating

Component Grades








Featured Post From StockTwits About CUE

$CUE "Members of the Cue Biopharma executive management team will provide a clinical update from the Company’s clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The discussion will focus on data updates from the Phase 1a/b monotherapy dose escalation and expansion trials, the combination trial evaluating CUE-101 front line with Merck’s pembrolizumab (KEYTRUDA®) and the upcoming neoadjuvant trial. Management will also provide an update on the Company’s technology platform developments and pipeline development progress from the IL-2 based CUE-100 series including CUE-102, as well as updates on its strategic objectives and anticipated milestones."
capital0708, published August 12, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!